Immunotherapy

Immunotherapy includes companies using the immune system to fight disease, especially cancer and autoimmune conditions. This can include checkpoint inhibitors, immune agonists, engineered immune cells, therapeutic vaccines, and other approaches that modify immune activity.

Why watch Immunotherapy

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Immunotherapy news

The latest feed items from companies currently grouped under Immunotherapy.

1. 01
   2026-10-06 12:00 EST

   PDSBPDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

   Source: PDS Biotechnology Corporation

2. 02
   2026-10-06 11:30 EST

   BCTXBriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

   Source: BriaCell

3. 03
   2026-10-05 13:00 EST

   MDNAMedicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

   Source: Medicenna Therapeutics Corp.

4. 04
   2026-10-02 20:30 EST

   XLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   Source: Xilio Therapeutics

5. 05
   2026-10-02 13:00 EST

   CADLCandel Therapeutics to Present at the SITC 2026 Annual Meeting

   Source: Candel Therapeutics

6. 06
   2026-10-02 13:00 EST

   INKTMiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

   Source: MiNK Therapeutics, Inc.

7. 07
   2026-10-02 11:00 EST

   RNACCartesian Therapeutics Announces New Employment Inducement Grants

   Source: Cartesian Therapeutics

8. 08
   2026-10-01 23:00 EST

   MDNAMedicenna Announces Results of Annual General and Special Meeting of Shareholders

   Source: Medicenna Therapeutics Corp.

9. 09
   2026-10-01 20:05 EST

   CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   Source: Candel Therapeutics

10. 10
    2026-10-01 20:01 EST

    REPLReplimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

    Source: Replimune Group

11. 11
    2026-10-01 12:05 EST

    CADLCandel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

    Source: Candel Therapeutics

12. 12
    2026-10-01 06:00 EST

    RHHBYRoche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions

    Source: Roche Holdings AG

13. 13
    2026-10-01 05:00 EST

    RHHBYRoche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine

    Source: Roche Holdings AG

14. 14
    2026-09-30 12:30 EST

    CADLCandel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

    Source: Candel Therapeutics

15. 15
    2026-09-30 12:05 EST

    CADLCandel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

    Source: Candel Therapeutics

16. 16
    2026-09-30 12:00 EST

    IMMPImmutep Receives ~A$0.86 Million R&D Tax Incentive

    Source: Immutep Limited

17. 17
    2026-09-30 11:57 EST

    INKTMiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

    Source: MiNK Therapeutics, Inc.

18. 18
    2026-09-30 05:00 EST

    RHHBYRoche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

    Source: Roche Holdings AG

19. 19
    2026-09-29 12:00 EST

    IMNNIMUNON Converts $1.2 Million of Debt-to-Equity

    Source: Imunon

20. 20
    2026-09-29 11:30 EST

    RNACCartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

    Source: Cartesian Therapeutics

Companies in Immunotherapy

68 companies tagged with Immunotherapy.

Frequently Asked Questions